Subsequent Development. The City shall not require Developer to obtain any approvals or permits for the development of the Project other than those permits or approvals which are required by the Applicable Rules or the Reserved Powers.
Subsequent Development. Owner may not proceed with any development or improvement of the Property other than as may be permitted under the terms of the Chaska City Code until such time as the Property has final plat approval from the City and Owner and other relevant parties have entered into a developer’s agreement which, amongst other matters, provides financial security acceptable to the City and has been approved by the City.
Subsequent Development. The Parties shall discuss and seek to align on Development activities intended to support lifecycle management of the Product following the Commercialization Date. 5.6
Subsequent Development. Except for the activities set forth in the Research Plan, the XEN901 Initial Development Plan, or the DTC Initial Development Plan, Neurocrine shall be solely responsible, at its sole cost and expense (but subject to the Co-Funding Option), for all Development of the Compounds and Products (the conduct of such activities is referred to herein as the “Subsequent Development”), including the conduct of a Phase 1b Clinical Trial (e.g., open-label study in patients) or Phase 2 Clinical Trial of a XEN901 Product in children with SCN8A-EE (as described in the XEN901 Neurocrine Development Plan, the “Proof of Concept Study”). Notwithstanding the foregoing, the Parties may mutually agree that Xenon will conduct particular activities with respect to the Subsequent Development of XEN901 or a DTC that are not included in an Initial Development Plan, in which case Neurocrine will reimburse all FTE Costs and out-of-pocket costs incurred by Xenon to conduct such activities.
Subsequent Development. Following completion of Initial Development, further Development, which shall include, without limitation, the preparation and filing of Marketing Authorization Applications and pursuit of Marketing Authorizations in the Territory (“Subsequent Development”) shall be governed by a Development Plan which shall be developed by Novacea promptly following completion of Initial Development, in consultation with KuDOS and any Third Party licensee of KuDOS with respect to the Product outside of the Territory, and regularly updated thereafter but not less than annually with specific reference to the anticipated timelines and allocation of responsibilities to the Parties. The Parties agree that, to the extent practicable, Subsequent Development shall occur in a manner consistent with a reasonable and diligent worldwide development program with respect to Product, and Novacea shall in good faith consult with KuDOS and its other licensees outside of the Territory with respect to Novacea’s plans for Phase 3 clinical trials, the preparation and filing of Marketing Authorization Applications and pursuit of Marketing Authorizations in the Territory. Notwithstanding the foregoing, Novacea shall have no obligation to develop Product in the Territory in any manner which Novacea concludes, after good faith consultation with KuDOS and its other licensees, is not consistent with the realization of maximum commercial benefit and sound scientific and medical practice in the Territory.
Subsequent Development. [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
Subsequent Development. Following the conclusion of the Development Plan Term in respect of a Product, ALEXION shall have sole control over, shall bear all costs and expenses of, and shall have sole discretion and decision-making authority with respect to, any further Development of such Product.
Subsequent Development. If Pfizer makes the Additional Milestone Payment, Pfizer shall thereafter become responsible for the remaining costs of completion of the Additional Trial (including by way of example continued patient monitoring, data collection and report writing). Pfizer may, at its option, either have its own personnel conduct such further work or may instruct Quark to carry out such work at mutually-agreed FTE rates which shall approximate Quark’s fully-loaded costs. Following payment of the Additional Milestone Payment, Pfizer shall once again be responsible for the further development and commercialization of the Licensed Product(s) at its own costs in accordance with the Agreement. Quark shall cooperate with Pfizer in all reasonable respects in transferring the Additional Trial to Pfizer, including transfer of any IND for PF-655 in its name to Pfizer and, to the extent permitted by its contracts, assigning any Third Party agreement related to the Additional Trial to Pfizer at Pfizer’s request. [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Subsequent Development. In addition to the initial Development Services contemplated in Section 3.2.1, Accuray agrees that it shall, to the extent reasonably requested by CyberHeart and agreed to by Accuray, provide subsequent Development Services during the Development Period under mutually agreed Statements of Work that shall enable CyberHeart to complete development of the CyberHeart Modules and CyberHeart Systems for applications in the CyberHeart Field. Accuray shall use Reasonable Commercial Efforts to accommodate CyberHeart’s requests during the Development Period for Development Services, including without limitation using Reasonable Commercial Efforts to accommodate any specifications and requirements requested by CyberHeart.
